Lipoprotein(a), or Lp(a), is a genetically determined low-density lipoprotein (LDL) subtype, which has been identified as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD).^1–3 The Lp(a) test is approved by the U.S. Food and Drug Administration; however, there are no universally accepted screening indications. The American College of Cardiology/American Heart Association (ACC/AHA) recommends screening for adults who have a family or personal history of premature ASCVD.⁴ The ACC/AHA further considers Lp(a) levels greater than 50 mg per dL (125 nmol per L) to be risk-enhancing for ASCVD.^1–12